

# Global Tumor Biomarker Testing Market 2026 by Company, Regions, Type and Application, Forecast to 2032

<https://marketpublishers.com/r/GE33691D6007EN.html>

Date: May 2026

Pages: 209

Price: US\$ 3,480.00 (Single User License)

ID: GE33691D6007EN

## Abstracts

According to our (Global Info Research) latest study, the global Tumor Biomarker Testing market size was valued at US\$ 12450 million in 2025 and is forecast to a readjusted size of US\$ 24843 million by 2032 with a CAGR of 10.4% during review period.

Tumor Biomarker Testing refers to the broad category of diagnostic products and testing services used to analyze measurable features associated with malignant tumors for diagnosis, classification, therapy selection, treatment monitoring, recurrence surveillance, and prognosis assessment. The analytes covered by Tumor Biomarker Testing may include protein markers, DNA mutations, RNA fusions, copy number variations, methylation signatures, microsatellite instability, tumor mutational burden, PD-L1 expression, circulating tumor DNA, and circulating tumor cells in tissue, blood, bone marrow, cells, or other body fluid samples. In commercial form, Tumor Biomarker Testing may appear as central-laboratory testing services, PCR kits, NGS panels, IHC/ISH reagents, cartridge-based automated systems, quality controls, and integrated software-reporting solutions. Its structure usually includes sample collection and preservation media, pre-analytical reagents, amplification or hybridization chemistry, signal detection instruments, bioinformatics interpretation modules, and clinical reporting. The core principle is to convert reproducible molecular or cellular abnormalities of cancer into clinically actionable information.

The growth of Tumor Biomarker Testing is fundamentally supported by the rising global cancer burden and the deeper penetration of precision oncology. With around 20 million new cancer cases worldwide in 2022 and a continued shift toward targeted therapy, immunotherapy, and biomarker-guided treatment, clinical practice is moving from single-

gene testing toward comprehensive biomarker testing and comprehensive genomic profiling. Guideline adoption and expanding drug-label linkage are driving demand for tissue testing, liquid biopsy, companion diagnostics, and MRD monitoring.

The major restraints remain access, reimbursement, standardization, and real-world implementation efficiency. Many patients still do not receive complete biomarker testing early enough in the treatment pathway, while tissue inadequacy, workflow fragmentation, inter-laboratory variability, low-shedding ctDNA, result interpretation complexity, and uneven payment coverage continue to limit adoption. For suppliers, regulatory compliance, evidence generation, quality systems, and secure data handling raise barriers to scale.

Downstream demand is shifting from one-time testing toward longitudinal, multi-sample, and multi-technology testing. Hospitals increasingly prefer integrated solutions that cover DNA, RNA, protein, and immune-related markers with faster turnaround and less tissue consumption. Advanced solid tumor care is moving toward broader pan-cancer panels and liquid biopsy, while post-surgical and treatment-monitoring settings are accelerating demand for ctDNA-MRD and recurrence surveillance. As a result, decentralized cartridge systems and centralized high-complexity genomic labs will continue to coexist, serving different clinical needs.

This report is a detailed and comprehensive analysis for global Tumor Biomarker Testing market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

### **Key Features:**

Global Tumor Biomarker Testing market size and forecasts, in consumption value (\$ Million), 2021-2032

Global Tumor Biomarker Testing market size and forecasts by region and country, in consumption value (\$ Million), 2021-2032

Global Tumor Biomarker Testing market size and forecasts, by Type and by Application, in consumption value (\$ Million), 2021-2032

Global Tumor Biomarker Testing market shares of main players, in revenue (\$ Million), 2021-2026

### **The Primary Objectives in This Report Are:**

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Tumor Biomarker Testing

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Tumor Biomarker Testing market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Abbott Laboratories, Agilent Technologies, Roche, Thermo Fisher Scientific, QIAGEN, Illumina, DiaSorin, Fujirebio, Siemens Healthineers, Quest Diagnostics, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

### Market segmentation

Tumor Biomarker Testing market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

### Market segment by Type

DNA Biomarker Testing

RNA Biomarker Testing

Protein Biomarker Testing

Cell-based Biomarker Testing

Multi-analyte Biomarker Testing

Market segment by Sample Source

Tissue-based Testing

Blood-based Testing

Bone Marrow-based Testing

Other Body Fluid-based Testing

Market segment by Delivery Model

Central Laboratory Testing

Hospital In-house Testing

Market segment by Detection Technology

Sequencing-based Testing

PCR-based Testing

Immunoassay-based Testing

Hybridization-based Testing

Cell Analysis-based Testing

Market segment by Application

Lung Cancer

Breast Cancer

Colorectal

Prostate Cancer

Blood Cancer

Market segment by players, this report covers

Abbott Laboratories

Agilent Technologies

Roche

Thermo Fisher Scientific

QIAGEN

Illumina

DiaSorin

Fujirebio

Siemens Healthineers

Quest Diagnostics

Labcorp

NeoGenomics

Exact Sciences

Myriad Genetics

Guardant Health

Caris Life Sciences

Tempus AI

Natera

Personalis

Invivoscribe

Biocartis

Sysmex

Leica Biosystems

Cepheid

Menarini Silicon Biosystems

Veracyte

Castle Biosciences

OncoDNA

ACT Genomics

GC Genome

Burning Rock

Amoy Diagnostics

Genetron Health

3DMed Diagnostics

Singlera Genomics

BGI Genomics

Geneseeq

Genecast

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

**The content of the study subjects, includes a total of 13 chapters:**

Chapter 1, to describe Tumor Biomarker Testing product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Tumor Biomarker Testing, with revenue, gross margin, and global market share of Tumor Biomarker Testing from 2021 to 2026.

Chapter 3, the Tumor Biomarker Testing competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026. and Tumor Biomarker Testing market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Tumor Biomarker Testing.

Chapter 13, to describe Tumor Biomarker Testing research findings and conclusion.

## Contents

### 1 MARKET OVERVIEW

1.1 Product Overview and Scope

1.2 Market Estimation Caveats and Base Year

1.3 Classification of Tumor Biomarker Testing by Type

1.3.1 Overview: Global Tumor Biomarker Testing Market Size by Type: 2021 Versus 2025 Versus 2032

1.3.2 Global Tumor Biomarker Testing Consumption Value Market Share by Type in 2025

1.3.3 DNA Biomarker Testing

1.3.4 RNA Biomarker Testing

1.3.5 Protein Biomarker Testing

1.3.6 Cell-based Biomarker Testing

1.3.7 Multi-analyte Biomarker Testing

1.4 Classification of Tumor Biomarker Testing by Sample Source

1.4.1 Overview: Global Tumor Biomarker Testing Market Size by Sample Source: 2021 Versus 2025 Versus 2032

1.4.2 Global Tumor Biomarker Testing Consumption Value Market Share by Sample Source in 2025

1.4.3 Tissue-based Testing

1.4.4 Blood-based Testing

1.4.5 Bone Marrow-based Testing

1.4.6 Other Body Fluid-based Testing

1.5 Classification of Tumor Biomarker Testing by Delivery Model

1.5.1 Overview: Global Tumor Biomarker Testing Market Size by Delivery Model: 2021 Versus 2025 Versus 2032

1.5.2 Global Tumor Biomarker Testing Consumption Value Market Share by Delivery Model in 2025

1.5.3 Central Laboratory Testing

1.5.4 Hospital In-house Testing

1.6 Classification of Tumor Biomarker Testing by Detection Technology

1.6.1 Overview: Global Tumor Biomarker Testing Market Size by Detection Technology: 2021 Versus 2025 Versus 2032

1.6.2 Global Tumor Biomarker Testing Consumption Value Market Share by Detection Technology in 2025

1.6.3 Sequencing-based Testing

1.6.4 PCR-based Testing

- 1.6.5 Immunoassay-based Testing
- 1.6.6 Hybridization-based Testing
- 1.6.7 Cell Analysis-based Testing
- 1.7 Global Tumor Biomarker Testing Market by Application
  - 1.7.1 Overview: Global Tumor Biomarker Testing Market Size by Application: 2021 Versus 2025 Versus 2032
  - 1.7.2 Lung Cancer
  - 1.7.3 Breast Cancer
  - 1.7.4 Colorectal
  - 1.7.5 Prostate Cancer
  - 1.7.6 Blood Cancer
- 1.8 Global Tumor Biomarker Testing Market Size & Forecast
- 1.9 Global Tumor Biomarker Testing Market Size and Forecast by Region
  - 1.9.1 Global Tumor Biomarker Testing Market Size by Region: 2021 VS 2025 VS 2032
  - 1.9.2 Global Tumor Biomarker Testing Market Size by Region, (2021-2032)
  - 1.9.3 North America Tumor Biomarker Testing Market Size and Prospect (2021-2032)
  - 1.9.4 Europe Tumor Biomarker Testing Market Size and Prospect (2021-2032)
  - 1.9.5 Asia-Pacific Tumor Biomarker Testing Market Size and Prospect (2021-2032)
  - 1.9.6 South America Tumor Biomarker Testing Market Size and Prospect (2021-2032)
  - 1.9.7 Middle East & Africa Tumor Biomarker Testing Market Size and Prospect (2021-2032)

## **2 COMPANY PROFILES**

- 2.1 Abbott Laboratories
  - 2.1.1 Abbott Laboratories Details
  - 2.1.2 Abbott Laboratories Major Business
  - 2.1.3 Abbott Laboratories Tumor Biomarker Testing Product and Solutions
  - 2.1.4 Abbott Laboratories Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
  - 2.1.5 Abbott Laboratories Recent Developments and Future Plans
- 2.2 Agilent Technologies
  - 2.2.1 Agilent Technologies Details
  - 2.2.2 Agilent Technologies Major Business
  - 2.2.3 Agilent Technologies Tumor Biomarker Testing Product and Solutions
  - 2.2.4 Agilent Technologies Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
  - 2.2.5 Agilent Technologies Recent Developments and Future Plans
- 2.3 Roche

- 2.3.1 Roche Details
- 2.3.2 Roche Major Business
- 2.3.3 Roche Tumor Biomarker Testing Product and Solutions
- 2.3.4 Roche Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Roche Recent Developments and Future Plans
- 2.4 Thermo Fisher Scientific
  - 2.4.1 Thermo Fisher Scientific Details
  - 2.4.2 Thermo Fisher Scientific Major Business
  - 2.4.3 Thermo Fisher Scientific Tumor Biomarker Testing Product and Solutions
  - 2.4.4 Thermo Fisher Scientific Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
  - 2.4.5 Thermo Fisher Scientific Recent Developments and Future Plans
- 2.5 QIAGEN
  - 2.5.1 QIAGEN Details
  - 2.5.2 QIAGEN Major Business
  - 2.5.3 QIAGEN Tumor Biomarker Testing Product and Solutions
  - 2.5.4 QIAGEN Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
  - 2.5.5 QIAGEN Recent Developments and Future Plans
- 2.6 Illumina
  - 2.6.1 Illumina Details
  - 2.6.2 Illumina Major Business
  - 2.6.3 Illumina Tumor Biomarker Testing Product and Solutions
  - 2.6.4 Illumina Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
  - 2.6.5 Illumina Recent Developments and Future Plans
- 2.7 DiaSorin
  - 2.7.1 DiaSorin Details
  - 2.7.2 DiaSorin Major Business
  - 2.7.3 DiaSorin Tumor Biomarker Testing Product and Solutions
  - 2.7.4 DiaSorin Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
  - 2.7.5 DiaSorin Recent Developments and Future Plans
- 2.8 Fujirebio
  - 2.8.1 Fujirebio Details
  - 2.8.2 Fujirebio Major Business
  - 2.8.3 Fujirebio Tumor Biomarker Testing Product and Solutions
  - 2.8.4 Fujirebio Tumor Biomarker Testing Revenue, Gross Margin and Market Share

(2021-2026)

2.8.5 Fujirebio Recent Developments and Future Plans

2.9 Siemens Healthineers

2.9.1 Siemens Healthineers Details

2.9.2 Siemens Healthineers Major Business

2.9.3 Siemens Healthineers Tumor Biomarker Testing Product and Solutions

2.9.4 Siemens Healthineers Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

2.9.5 Siemens Healthineers Recent Developments and Future Plans

2.10 Quest Diagnostics

2.10.1 Quest Diagnostics Details

2.10.2 Quest Diagnostics Major Business

2.10.3 Quest Diagnostics Tumor Biomarker Testing Product and Solutions

2.10.4 Quest Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

2.10.5 Quest Diagnostics Recent Developments and Future Plans

2.11 Labcorp

2.11.1 Labcorp Details

2.11.2 Labcorp Major Business

2.11.3 Labcorp Tumor Biomarker Testing Product and Solutions

2.11.4 Labcorp Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

2.11.5 Labcorp Recent Developments and Future Plans

2.12 NeoGenomics

2.12.1 NeoGenomics Details

2.12.2 NeoGenomics Major Business

2.12.3 NeoGenomics Tumor Biomarker Testing Product and Solutions

2.12.4 NeoGenomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

2.12.5 NeoGenomics Recent Developments and Future Plans

2.13 Exact Sciences

2.13.1 Exact Sciences Details

2.13.2 Exact Sciences Major Business

2.13.3 Exact Sciences Tumor Biomarker Testing Product and Solutions

2.13.4 Exact Sciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

2.13.5 Exact Sciences Recent Developments and Future Plans

2.14 Myriad Genetics

2.14.1 Myriad Genetics Details

- 2.14.2 Myriad Genetics Major Business
- 2.14.3 Myriad Genetics Tumor Biomarker Testing Product and Solutions
- 2.14.4 Myriad Genetics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
- 2.14.5 Myriad Genetics Recent Developments and Future Plans
- 2.15 Guardant Health
  - 2.15.1 Guardant Health Details
  - 2.15.2 Guardant Health Major Business
  - 2.15.3 Guardant Health Tumor Biomarker Testing Product and Solutions
  - 2.15.4 Guardant Health Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
  - 2.15.5 Guardant Health Recent Developments and Future Plans
- 2.16 Caris Life Sciences
  - 2.16.1 Caris Life Sciences Details
  - 2.16.2 Caris Life Sciences Major Business
  - 2.16.3 Caris Life Sciences Tumor Biomarker Testing Product and Solutions
  - 2.16.4 Caris Life Sciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
  - 2.16.5 Caris Life Sciences Recent Developments and Future Plans
- 2.17 Tempus AI
  - 2.17.1 Tempus AI Details
  - 2.17.2 Tempus AI Major Business
  - 2.17.3 Tempus AI Tumor Biomarker Testing Product and Solutions
  - 2.17.4 Tempus AI Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
  - 2.17.5 Tempus AI Recent Developments and Future Plans
- 2.18 Natera
  - 2.18.1 Natera Details
  - 2.18.2 Natera Major Business
  - 2.18.3 Natera Tumor Biomarker Testing Product and Solutions
  - 2.18.4 Natera Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
  - 2.18.5 Natera Recent Developments and Future Plans
- 2.19 Personalis
  - 2.19.1 Personalis Details
  - 2.19.2 Personalis Major Business
  - 2.19.3 Personalis Tumor Biomarker Testing Product and Solutions
  - 2.19.4 Personalis Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

- 2.19.5 Personalis Recent Developments and Future Plans
- 2.20 Invivoscribe
  - 2.20.1 Invivoscribe Details
  - 2.20.2 Invivoscribe Major Business
  - 2.20.3 Invivoscribe Tumor Biomarker Testing Product and Solutions
  - 2.20.4 Invivoscribe Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
  - 2.20.5 Invivoscribe Recent Developments and Future Plans
- 2.21 Biocartis
  - 2.21.1 Biocartis Details
  - 2.21.2 Biocartis Major Business
  - 2.21.3 Biocartis Tumor Biomarker Testing Product and Solutions
  - 2.21.4 Biocartis Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
  - 2.21.5 Biocartis Recent Developments and Future Plans
- 2.22 Sysmex
  - 2.22.1 Sysmex Details
  - 2.22.2 Sysmex Major Business
  - 2.22.3 Sysmex Tumor Biomarker Testing Product and Solutions
  - 2.22.4 Sysmex Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
  - 2.22.5 Sysmex Recent Developments and Future Plans
- 2.23 Leica Biosystems
  - 2.23.1 Leica Biosystems Details
  - 2.23.2 Leica Biosystems Major Business
  - 2.23.3 Leica Biosystems Tumor Biomarker Testing Product and Solutions
  - 2.23.4 Leica Biosystems Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
  - 2.23.5 Leica Biosystems Recent Developments and Future Plans
- 2.24 Cepheid
  - 2.24.1 Cepheid Details
  - 2.24.2 Cepheid Major Business
  - 2.24.3 Cepheid Tumor Biomarker Testing Product and Solutions
  - 2.24.4 Cepheid Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
  - 2.24.5 Cepheid Recent Developments and Future Plans
- 2.25 Menarini Silicon Biosystems
  - 2.25.1 Menarini Silicon Biosystems Details
  - 2.25.2 Menarini Silicon Biosystems Major Business

- 2.25.3 Menarini Silicon Biosystems Tumor Biomarker Testing Product and Solutions
- 2.25.4 Menarini Silicon Biosystems Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
- 2.25.5 Menarini Silicon Biosystems Recent Developments and Future Plans
- 2.26 Veracyte
  - 2.26.1 Veracyte Details
  - 2.26.2 Veracyte Major Business
  - 2.26.3 Veracyte Tumor Biomarker Testing Product and Solutions
  - 2.26.4 Veracyte Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
  - 2.26.5 Veracyte Recent Developments and Future Plans
- 2.27 Castle Biosciences
  - 2.27.1 Castle Biosciences Details
  - 2.27.2 Castle Biosciences Major Business
  - 2.27.3 Castle Biosciences Tumor Biomarker Testing Product and Solutions
  - 2.27.4 Castle Biosciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
  - 2.27.5 Castle Biosciences Recent Developments and Future Plans
- 2.28 OncoDNA
  - 2.28.1 OncoDNA Details
  - 2.28.2 OncoDNA Major Business
  - 2.28.3 OncoDNA Tumor Biomarker Testing Product and Solutions
  - 2.28.4 OncoDNA Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
  - 2.28.5 OncoDNA Recent Developments and Future Plans
- 2.29 ACT Genomics
  - 2.29.1 ACT Genomics Details
  - 2.29.2 ACT Genomics Major Business
  - 2.29.3 ACT Genomics Tumor Biomarker Testing Product and Solutions
  - 2.29.4 ACT Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
  - 2.29.5 ACT Genomics Recent Developments and Future Plans
- 2.30 GC Genome
  - 2.30.1 GC Genome Details
  - 2.30.2 GC Genome Major Business
  - 2.30.3 GC Genome Tumor Biomarker Testing Product and Solutions
  - 2.30.4 GC Genome Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
  - 2.30.5 GC Genome Recent Developments and Future Plans

## 2.31 Burning Rock

2.31.1 Burning Rock Details

2.31.2 Burning Rock Major Business

2.31.3 Burning Rock Tumor Biomarker Testing Product and Solutions

2.31.4 Burning Rock Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

2.31.5 Burning Rock Recent Developments and Future Plans

## 2.32 Amoy Diagnostics

2.32.1 Amoy Diagnostics Details

2.32.2 Amoy Diagnostics Major Business

2.32.3 Amoy Diagnostics Tumor Biomarker Testing Product and Solutions

2.32.4 Amoy Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

2.32.5 Amoy Diagnostics Recent Developments and Future Plans

## 2.33 Genetron Health

2.33.1 Genetron Health Details

2.33.2 Genetron Health Major Business

2.33.3 Genetron Health Tumor Biomarker Testing Product and Solutions

2.33.4 Genetron Health Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

2.33.5 Genetron Health Recent Developments and Future Plans

## 2.34 3DMed Diagnostics

2.34.1 3DMed Diagnostics Details

2.34.2 3DMed Diagnostics Major Business

2.34.3 3DMed Diagnostics Tumor Biomarker Testing Product and Solutions

2.34.4 3DMed Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

2.34.5 3DMed Diagnostics Recent Developments and Future Plans

## 2.35 Singlera Genomics

2.35.1 Singlera Genomics Details

2.35.2 Singlera Genomics Major Business

2.35.3 Singlera Genomics Tumor Biomarker Testing Product and Solutions

2.35.4 Singlera Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

2.35.5 Singlera Genomics Recent Developments and Future Plans

## 2.36 BGI Genomics

2.36.1 BGI Genomics Details

2.36.2 BGI Genomics Major Business

2.36.3 BGI Genomics Tumor Biomarker Testing Product and Solutions

2.36.4 BGI Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

2.36.5 BGI Genomics Recent Developments and Future Plans

2.37 Geneseeq

2.37.1 Geneseeq Details

2.37.2 Geneseeq Major Business

2.37.3 Geneseeq Tumor Biomarker Testing Product and Solutions

2.37.4 Geneseeq Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

2.37.5 Geneseeq Recent Developments and Future Plans

2.38 Genecast

2.38.1 Genecast Details

2.38.2 Genecast Major Business

2.38.3 Genecast Tumor Biomarker Testing Product and Solutions

2.38.4 Genecast Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

2.38.5 Genecast Recent Developments and Future Plans

### **3 MARKET COMPETITION, BY PLAYERS**

3.1 Global Tumor Biomarker Testing Revenue and Share by Players (2021-2026)

3.2 Market Share Analysis (2025)

3.2.1 Market Share of Tumor Biomarker Testing by Company Revenue

3.2.2 Top 3 Tumor Biomarker Testing Players Market Share in 2025

3.2.3 Top 6 Tumor Biomarker Testing Players Market Share in 2025

3.3 Tumor Biomarker Testing Market: Overall Company Footprint Analysis

3.3.1 Tumor Biomarker Testing Market: Region Footprint

3.3.2 Tumor Biomarker Testing Market: Company Product Type Footprint

3.3.3 Tumor Biomarker Testing Market: Company Product Application Footprint

3.4 New Market Entrants and Barriers to Market Entry

3.5 Mergers, Acquisition, Agreements, and Collaborations

### **4 MARKET SIZE SEGMENT BY TYPE**

4.1 Global Tumor Biomarker Testing Consumption Value and Market Share by Type (2021-2026)

4.2 Global Tumor Biomarker Testing Market Forecast by Type (2027-2032)

### **5 MARKET SIZE SEGMENT BY APPLICATION**

5.1 Global Tumor Biomarker Testing Consumption Value Market Share by Application (2021-2026)

5.2 Global Tumor Biomarker Testing Market Forecast by Application (2027-2032)

## **6 NORTH AMERICA**

6.1 North America Tumor Biomarker Testing Consumption Value by Type (2021-2032)

6.2 North America Tumor Biomarker Testing Market Size by Application (2021-2032)

6.3 North America Tumor Biomarker Testing Market Size by Country

6.3.1 North America Tumor Biomarker Testing Consumption Value by Country (2021-2032)

6.3.2 United States Tumor Biomarker Testing Market Size and Forecast (2021-2032)

6.3.3 Canada Tumor Biomarker Testing Market Size and Forecast (2021-2032)

6.3.4 Mexico Tumor Biomarker Testing Market Size and Forecast (2021-2032)

## **7 EUROPE**

7.1 Europe Tumor Biomarker Testing Consumption Value by Type (2021-2032)

7.2 Europe Tumor Biomarker Testing Consumption Value by Application (2021-2032)

7.3 Europe Tumor Biomarker Testing Market Size by Country

7.3.1 Europe Tumor Biomarker Testing Consumption Value by Country (2021-2032)

7.3.2 Germany Tumor Biomarker Testing Market Size and Forecast (2021-2032)

7.3.3 France Tumor Biomarker Testing Market Size and Forecast (2021-2032)

7.3.4 United Kingdom Tumor Biomarker Testing Market Size and Forecast (2021-2032)

7.3.5 Russia Tumor Biomarker Testing Market Size and Forecast (2021-2032)

7.3.6 Italy Tumor Biomarker Testing Market Size and Forecast (2021-2032)

## **8 ASIA-PACIFIC**

8.1 Asia-Pacific Tumor Biomarker Testing Consumption Value by Type (2021-2032)

8.2 Asia-Pacific Tumor Biomarker Testing Consumption Value by Application (2021-2032)

8.3 Asia-Pacific Tumor Biomarker Testing Market Size by Region

8.3.1 Asia-Pacific Tumor Biomarker Testing Consumption Value by Region (2021-2032)

8.3.2 China Tumor Biomarker Testing Market Size and Forecast (2021-2032)

8.3.3 Japan Tumor Biomarker Testing Market Size and Forecast (2021-2032)

- 8.3.4 South Korea Tumor Biomarker Testing Market Size and Forecast (2021-2032)
- 8.3.5 India Tumor Biomarker Testing Market Size and Forecast (2021-2032)
- 8.3.6 Southeast Asia Tumor Biomarker Testing Market Size and Forecast (2021-2032)
- 8.3.7 Australia Tumor Biomarker Testing Market Size and Forecast (2021-2032)

## **9 SOUTH AMERICA**

- 9.1 South America Tumor Biomarker Testing Consumption Value by Type (2021-2032)
- 9.2 South America Tumor Biomarker Testing Consumption Value by Application (2021-2032)
- 9.3 South America Tumor Biomarker Testing Market Size by Country
  - 9.3.1 South America Tumor Biomarker Testing Consumption Value by Country (2021-2032)
  - 9.3.2 Brazil Tumor Biomarker Testing Market Size and Forecast (2021-2032)
  - 9.3.3 Argentina Tumor Biomarker Testing Market Size and Forecast (2021-2032)

## **10 MIDDLE EAST & AFRICA**

- 10.1 Middle East & Africa Tumor Biomarker Testing Consumption Value by Type (2021-2032)
- 10.2 Middle East & Africa Tumor Biomarker Testing Consumption Value by Application (2021-2032)
- 10.3 Middle East & Africa Tumor Biomarker Testing Market Size by Country
  - 10.3.1 Middle East & Africa Tumor Biomarker Testing Consumption Value by Country (2021-2032)
  - 10.3.2 Turkey Tumor Biomarker Testing Market Size and Forecast (2021-2032)
  - 10.3.3 Saudi Arabia Tumor Biomarker Testing Market Size and Forecast (2021-2032)
  - 10.3.4 UAE Tumor Biomarker Testing Market Size and Forecast (2021-2032)

## **11 MARKET DYNAMICS**

- 11.1 Tumor Biomarker Testing Market Drivers
- 11.2 Tumor Biomarker Testing Market Restraints
- 11.3 Tumor Biomarker Testing Trends Analysis
- 11.4 Porters Five Forces Analysis
  - 11.4.1 Threat of New Entrants
  - 11.4.2 Bargaining Power of Suppliers
  - 11.4.3 Bargaining Power of Buyers
  - 11.4.4 Threat of Substitutes

11.4.5 Competitive Rivalry

## **12 INDUSTRY CHAIN ANALYSIS**

12.1 Tumor Biomarker Testing Industry Chain

12.2 Tumor Biomarker Testing Upstream Analysis

12.3 Tumor Biomarker Testing Midstream Analysis

12.4 Tumor Biomarker Testing Downstream Analysis

## **13 RESEARCH FINDINGS AND CONCLUSION**

## **14 APPENDIX**

14.1 Methodology

14.2 Research Process and Data Source

14.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. Global Tumor Biomarker Testing Consumption Value by Type, (USD Million), 2021 & 2025 & 2032

Table 2. Global Tumor Biomarker Testing Consumption Value by Sample Source, (USD Million), 2021 & 2025 & 2032

Table 3. Global Tumor Biomarker Testing Consumption Value by Delivery Model, (USD Million), 2021 & 2025 & 2032

Table 4. Global Tumor Biomarker Testing Consumption Value by Detection Technology, (USD Million), 2021 & 2025 & 2032

Table 5. Global Tumor Biomarker Testing Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Table 6. Global Tumor Biomarker Testing Consumption Value by Region (2021-2026) & (USD Million)

Table 7. Global Tumor Biomarker Testing Consumption Value by Region (2027-2032) & (USD Million)

Table 8. Abbott Laboratories Company Information, Head Office, and Major Competitors

Table 9. Abbott Laboratories Major Business

Table 10. Abbott Laboratories Tumor Biomarker Testing Product and Solutions

Table 11. Abbott Laboratories Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 12. Abbott Laboratories Recent Developments and Future Plans

Table 13. Agilent Technologies Company Information, Head Office, and Major Competitors

Table 14. Agilent Technologies Major Business

Table 15. Agilent Technologies Tumor Biomarker Testing Product and Solutions

Table 16. Agilent Technologies Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 17. Agilent Technologies Recent Developments and Future Plans

Table 18. Roche Company Information, Head Office, and Major Competitors

Table 19. Roche Major Business

Table 20. Roche Tumor Biomarker Testing Product and Solutions

Table 21. Roche Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 22. Thermo Fisher Scientific Company Information, Head Office, and Major Competitors

Table 23. Thermo Fisher Scientific Major Business

- Table 24. Thermo Fisher Scientific Tumor Biomarker Testing Product and Solutions
- Table 25. Thermo Fisher Scientific Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 26. Thermo Fisher Scientific Recent Developments and Future Plans
- Table 27. QIAGEN Company Information, Head Office, and Major Competitors
- Table 28. QIAGEN Major Business
- Table 29. QIAGEN Tumor Biomarker Testing Product and Solutions
- Table 30. QIAGEN Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 31. QIAGEN Recent Developments and Future Plans
- Table 32. Illumina Company Information, Head Office, and Major Competitors
- Table 33. Illumina Major Business
- Table 34. Illumina Tumor Biomarker Testing Product and Solutions
- Table 35. Illumina Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 36. Illumina Recent Developments and Future Plans
- Table 37. DiaSorin Company Information, Head Office, and Major Competitors
- Table 38. DiaSorin Major Business
- Table 39. DiaSorin Tumor Biomarker Testing Product and Solutions
- Table 40. DiaSorin Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 41. DiaSorin Recent Developments and Future Plans
- Table 42. Fujirebio Company Information, Head Office, and Major Competitors
- Table 43. Fujirebio Major Business
- Table 44. Fujirebio Tumor Biomarker Testing Product and Solutions
- Table 45. Fujirebio Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 46. Fujirebio Recent Developments and Future Plans
- Table 47. Siemens Healthineers Company Information, Head Office, and Major Competitors
- Table 48. Siemens Healthineers Major Business
- Table 49. Siemens Healthineers Tumor Biomarker Testing Product and Solutions
- Table 50. Siemens Healthineers Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 51. Siemens Healthineers Recent Developments and Future Plans
- Table 52. Quest Diagnostics Company Information, Head Office, and Major Competitors
- Table 53. Quest Diagnostics Major Business
- Table 54. Quest Diagnostics Tumor Biomarker Testing Product and Solutions
- Table 55. Quest Diagnostics Tumor Biomarker Testing Revenue (USD Million), Gross

Margin and Market Share (2021-2026)

Table 56. Quest Diagnostics Recent Developments and Future Plans

Table 57. Labcorp Company Information, Head Office, and Major Competitors

Table 58. Labcorp Major Business

Table 59. Labcorp Tumor Biomarker Testing Product and Solutions

Table 60. Labcorp Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 61. Labcorp Recent Developments and Future Plans

Table 62. NeoGenomics Company Information, Head Office, and Major Competitors

Table 63. NeoGenomics Major Business

Table 64. NeoGenomics Tumor Biomarker Testing Product and Solutions

Table 65. NeoGenomics Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 66. NeoGenomics Recent Developments and Future Plans

Table 67. Exact Sciences Company Information, Head Office, and Major Competitors

Table 68. Exact Sciences Major Business

Table 69. Exact Sciences Tumor Biomarker Testing Product and Solutions

Table 70. Exact Sciences Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 71. Exact Sciences Recent Developments and Future Plans

Table 72. Myriad Genetics Company Information, Head Office, and Major Competitors

Table 73. Myriad Genetics Major Business

Table 74. Myriad Genetics Tumor Biomarker Testing Product and Solutions

Table 75. Myriad Genetics Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 76. Myriad Genetics Recent Developments and Future Plans

Table 77. Guardant Health Company Information, Head Office, and Major Competitors

Table 78. Guardant Health Major Business

Table 79. Guardant Health Tumor Biomarker Testing Product and Solutions

Table 80. Guardant Health Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 81. Guardant Health Recent Developments and Future Plans

Table 82. Caris Life Sciences Company Information, Head Office, and Major Competitors

Table 83. Caris Life Sciences Major Business

Table 84. Caris Life Sciences Tumor Biomarker Testing Product and Solutions

Table 85. Caris Life Sciences Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 86. Caris Life Sciences Recent Developments and Future Plans

Table 87. Tempus AI Company Information, Head Office, and Major Competitors

Table 88. Tempus AI Major Business

Table 89. Tempus AI Tumor Biomarker Testing Product and Solutions

Table 90. Tempus AI Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 91. Tempus AI Recent Developments and Future Plans

Table 92. Natera Company Information, Head Office, and Major Competitors

Table 93. Natera Major Business

Table 94. Natera Tumor Biomarker Testing Product and Solutions

Table 95. Natera Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 96. Natera Recent Developments and Future Plans

Table 97. Personalis Company Information, Head Office, and Major Competitors

Table 98. Personalis Major Business

Table 99. Personalis Tumor Biomarker Testing Product and Solutions

Table 100. Personalis Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 101. Personalis Recent Developments and Future Plans

Table 102. Invivoscribe Company Information, Head Office, and Major Competitors

Table 103. Invivoscribe Major Business

Table 104. Invivoscribe Tumor Biomarker Testing Product and Solutions

Table 105. Invivoscribe Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 106. Invivoscribe Recent Developments and Future Plans

Table 107. Biocartis Company Information, Head Office, and Major Competitors

Table 108. Biocartis Major Business

Table 109. Biocartis Tumor Biomarker Testing Product and Solutions

Table 110. Biocartis Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 111. Biocartis Recent Developments and Future Plans

Table 112. Sysmex Company Information, Head Office, and Major Competitors

Table 113. Sysmex Major Business

Table 114. Sysmex Tumor Biomarker Testing Product and Solutions

Table 115. Sysmex Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 116. Sysmex Recent Developments and Future Plans

Table 117. Leica Biosystems Company Information, Head Office, and Major Competitors

Table 118. Leica Biosystems Major Business

- Table 119. Leica Biosystems Tumor Biomarker Testing Product and Solutions
- Table 120. Leica Biosystems Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 121. Leica Biosystems Recent Developments and Future Plans
- Table 122. Cepheid Company Information, Head Office, and Major Competitors
- Table 123. Cepheid Major Business
- Table 124. Cepheid Tumor Biomarker Testing Product and Solutions
- Table 125. Cepheid Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 126. Cepheid Recent Developments and Future Plans
- Table 127. Menarini Silicon Biosystems Company Information, Head Office, and Major Competitors
- Table 128. Menarini Silicon Biosystems Major Business
- Table 129. Menarini Silicon Biosystems Tumor Biomarker Testing Product and Solutions
- Table 130. Menarini Silicon Biosystems Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 131. Menarini Silicon Biosystems Recent Developments and Future Plans
- Table 132. Veracyte Company Information, Head Office, and Major Competitors
- Table 133. Veracyte Major Business
- Table 134. Veracyte Tumor Biomarker Testing Product and Solutions
- Table 135. Veracyte Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 136. Veracyte Recent Developments and Future Plans
- Table 137. Castle Biosciences Company Information, Head Office, and Major Competitors
- Table 138. Castle Biosciences Major Business
- Table 139. Castle Biosciences Tumor Biomarker Testing Product and Solutions
- Table 140. Castle Biosciences Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 141. Castle Biosciences Recent Developments and Future Plans
- Table 142. OncoDNA Company Information, Head Office, and Major Competitors
- Table 143. OncoDNA Major Business
- Table 144. OncoDNA Tumor Biomarker Testing Product and Solutions
- Table 145. OncoDNA Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 146. OncoDNA Recent Developments and Future Plans
- Table 147. ACT Genomics Company Information, Head Office, and Major Competitors
- Table 148. ACT Genomics Major Business

- Table 149. ACT Genomics Tumor Biomarker Testing Product and Solutions
- Table 150. ACT Genomics Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 151. ACT Genomics Recent Developments and Future Plans
- Table 152. GC Genome Company Information, Head Office, and Major Competitors
- Table 153. GC Genome Major Business
- Table 154. GC Genome Tumor Biomarker Testing Product and Solutions
- Table 155. GC Genome Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 156. GC Genome Recent Developments and Future Plans
- Table 157. Burning Rock Company Information, Head Office, and Major Competitors
- Table 158. Burning Rock Major Business
- Table 159. Burning Rock Tumor Biomarker Testing Product and Solutions
- Table 160. Burning Rock Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 161. Burning Rock Recent Developments and Future Plans
- Table 162. Amoy Diagnostics Company Information, Head Office, and Major Competitors
- Table 163. Amoy Diagnostics Major Business
- Table 164. Amoy Diagnostics Tumor Biomarker Testing Product and Solutions
- Table 165. Amoy Diagnostics Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 166. Amoy Diagnostics Recent Developments and Future Plans
- Table 167. Genetron Health Company Information, Head Office, and Major Competitors
- Table 168. Genetron Health Major Business
- Table 169. Genetron Health Tumor Biomarker Testing Product and Solutions
- Table 170. Genetron Health Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 171. Genetron Health Recent Developments and Future Plans
- Table 172. 3DMed Diagnostics Company Information, Head Office, and Major Competitors
- Table 173. 3DMed Diagnostics Major Business
- Table 174. 3DMed Diagnostics Tumor Biomarker Testing Product and Solutions
- Table 175. 3DMed Diagnostics Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 176. 3DMed Diagnostics Recent Developments and Future Plans
- Table 177. Singlera Genomics Company Information, Head Office, and Major Competitors
- Table 178. Singlera Genomics Major Business

- Table 179. Singlera Genomics Tumor Biomarker Testing Product and Solutions
- Table 180. Singlera Genomics Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 181. Singlera Genomics Recent Developments and Future Plans
- Table 182. BGI Genomics Company Information, Head Office, and Major Competitors
- Table 183. BGI Genomics Major Business
- Table 184. BGI Genomics Tumor Biomarker Testing Product and Solutions
- Table 185. BGI Genomics Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 186. BGI Genomics Recent Developments and Future Plans
- Table 187. Geneseeq Company Information, Head Office, and Major Competitors
- Table 188. Geneseeq Major Business
- Table 189. Geneseeq Tumor Biomarker Testing Product and Solutions
- Table 190. Geneseeq Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 191. Geneseeq Recent Developments and Future Plans
- Table 192. Genecast Company Information, Head Office, and Major Competitors
- Table 193. Genecast Major Business
- Table 194. Genecast Tumor Biomarker Testing Product and Solutions
- Table 195. Genecast Tumor Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 196. Genecast Recent Developments and Future Plans
- Table 197. Global Tumor Biomarker Testing Revenue (USD Million) by Players (2021-2026)
- Table 198. Global Tumor Biomarker Testing Revenue Share by Players (2021-2026)
- Table 199. Breakdown of Tumor Biomarker Testing by Company Type (Tier 1, Tier 2, and Tier 3)
- Table 200. Market Position of Players in Tumor Biomarker Testing, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
- Table 201. Head Office of Key Tumor Biomarker Testing Players
- Table 202. Tumor Biomarker Testing Market: Company Product Type Footprint
- Table 203. Tumor Biomarker Testing Market: Company Product Application Footprint
- Table 204. Tumor Biomarker Testing New Market Entrants and Barriers to Market Entry
- Table 205. Tumor Biomarker Testing Mergers, Acquisition, Agreements, and Collaborations
- Table 206. Global Tumor Biomarker Testing Consumption Value (USD Million) by Type (2021-2026)
- Table 207. Global Tumor Biomarker Testing Consumption Value Share by Type (2021-2026)

Table 208. Global Tumor Biomarker Testing Consumption Value Forecast by Type (2027-2032)

Table 209. Global Tumor Biomarker Testing Consumption Value by Application (2021-2026)

Table 210. Global Tumor Biomarker Testing Consumption Value Forecast by Application (2027-2032)

Table 211. North America Tumor Biomarker Testing Consumption Value by Type (2021-2026) & (USD Million)

Table 212. North America Tumor Biomarker Testing Consumption Value by Type (2027-2032) & (USD Million)

Table 213. North America Tumor Biomarker Testing Consumption Value by Application (2021-2026) & (USD Million)

Table 214. North America Tumor Biomarker Testing Consumption Value by Application (2027-2032) & (USD Million)

Table 215. North America Tumor Biomarker Testing Consumption Value by Country (2021-2026) & (USD Million)

Table 216. North America Tumor Biomarker Testing Consumption Value by Country (2027-2032) & (USD Million)

Table 217. Europe Tumor Biomarker Testing Consumption Value by Type (2021-2026) & (USD Million)

Table 218. Europe Tumor Biomarker Testing Consumption Value by Type (2027-2032) & (USD Million)

Table 219. Europe Tumor Biomarker Testing Consumption Value by Application (2021-2026) & (USD Million)

Table 220. Europe Tumor Biomarker Testing Consumption Value by Application (2027-2032) & (USD Million)

Table 221. Europe Tumor Biomarker Testing Consumption Value by Country (2021-2026) & (USD Million)

Table 222. Europe Tumor Biomarker Testing Consumption Value by Country (2027-2032) & (USD Million)

Table 223. Asia-Pacific Tumor Biomarker Testing Consumption Value by Type (2021-2026) & (USD Million)

Table 224. Asia-Pacific Tumor Biomarker Testing Consumption Value by Type (2027-2032) & (USD Million)

Table 225. Asia-Pacific Tumor Biomarker Testing Consumption Value by Application (2021-2026) & (USD Million)

Table 226. Asia-Pacific Tumor Biomarker Testing Consumption Value by Application (2027-2032) & (USD Million)

Table 227. Asia-Pacific Tumor Biomarker Testing Consumption Value by Region

(2021-2026) & (USD Million)

Table 228. Asia-Pacific Tumor Biomarker Testing Consumption Value by Region

(2027-2032) & (USD Million)

Table 229. South America Tumor Biomarker Testing Consumption Value by Type

(2021-2026) & (USD Million)

Table 230. South America Tumor Biomarker Testing Consumption Value by Type

(2027-2032) & (USD Million)

Table 231. South America Tumor Biomarker Testing Consumption Value by Application

(2021-2026) & (USD Million)

Table 232. South America Tumor Biomarker Testing Consumption Value by Application

(2027-2032) & (USD Million)

Table 233. South America Tumor Biomarker Testing Consumption Value by Country

(2021-2026) & (USD Million)

Table 234. South America Tumor Biomarker Testing Consumption Value by Country

(2027-2032) & (USD Million)

Table 235. Middle East & Africa Tumor Biomarker Testing Consumption Value by Type

(2021-2026) & (USD Million)

Table 236. Middle East & Africa Tumor Biomarker Testing Consumption Value by Type

(2027-2032) & (USD Million)

Table 237. Middle East & Africa Tumor Biomarker Testing Consumption Value by Application (2021-2026) & (USD Million)

Table 238. Middle East & Africa Tumor Biomarker Testing Consumption Value by Application (2027-2032) & (USD Million)

Table 239. Middle East & Africa Tumor Biomarker Testing Consumption Value by Country (2021-2026) & (USD Million)

Table 240. Middle East & Africa Tumor Biomarker Testing Consumption Value by Country (2027-2032) & (USD Million)

Table 241. Global Key Players of Tumor Biomarker Testing Upstream (Raw Materials)

Table 242. Global Tumor Biomarker Testing Typical Customers

## List Of Figures

### LIST OF FIGURES

- Figure 1. Tumor Biomarker Testing Picture
- Figure 2. Global Tumor Biomarker Testing Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
- Figure 3. Global Tumor Biomarker Testing Consumption Value Market Share by Type in 2025
- Figure 4. DNA Biomarker Testing
- Figure 5. RNA Biomarker Testing
- Figure 6. Protein Biomarker Testing
- Figure 7. Cell-based Biomarker Testing
- Figure 8. Multi-analyte Biomarker Testing
- Figure 9. Global Tumor Biomarker Testing Consumption Value by Sample Source, (USD Million), 2021 & 2025 & 2032
- Figure 10. Global Tumor Biomarker Testing Consumption Value Market Share by Sample Source in 2025
- Figure 11. Tissue-based Testing
- Figure 12. Blood-based Testing
- Figure 13. Bone Marrow-based Testing
- Figure 14. Other Body Fluid-based Testing
- Figure 15. Global Tumor Biomarker Testing Consumption Value by Delivery Model, (USD Million), 2021 & 2025 & 2032
- Figure 16. Global Tumor Biomarker Testing Consumption Value Market Share by Delivery Model in 2025
- Figure 17. Central Laboratory Testing
- Figure 18. Hospital In-house Testing
- Figure 19. Global Tumor Biomarker Testing Consumption Value by Detection Technology, (USD Million), 2021 & 2025 & 2032
- Figure 20. Global Tumor Biomarker Testing Consumption Value Market Share by Detection Technology in 2025
- Figure 21. Sequencing-based Testing
- Figure 22. PCR-based Testing
- Figure 23. Immunoassay-based Testing
- Figure 24. Hybridization-based Testing
- Figure 25. Cell Analysis-based Testing
- Figure 26. Global Tumor Biomarker Testing Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Figure 27. Tumor Biomarker Testing Consumption Value Market Share by Application in 2025

Figure 28. Lung Cancer Picture

Figure 29. Breast Cancer Picture

Figure 30. Colorectal Picture

Figure 31. Prostate Cancer Picture

Figure 32. Blood Cancer Picture

Figure 33. Global Tumor Biomarker Testing Consumption Value, (USD Million): 2021 & 2025 & 2032

Figure 34. Global Tumor Biomarker Testing Consumption Value and Forecast (2021-2032) & (USD Million)

Figure 35. Global Market Tumor Biomarker Testing Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)

Figure 36. Global Tumor Biomarker Testing Consumption Value Market Share by Region (2021-2032)

Figure 37. Global Tumor Biomarker Testing Consumption Value Market Share by Region in 2025

Figure 38. North America Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 39. Europe Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 40. Asia-Pacific Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 41. South America Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 42. Middle East & Africa Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 43. Company Three Recent Developments and Future Plans

Figure 44. Global Tumor Biomarker Testing Revenue Share by Players in 2025

Figure 45. Tumor Biomarker Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025

Figure 46. Market Share of Tumor Biomarker Testing by Player Revenue in 2025

Figure 47. Top 3 Tumor Biomarker Testing Players Market Share in 2025

Figure 48. Top 6 Tumor Biomarker Testing Players Market Share in 2025

Figure 49. Global Tumor Biomarker Testing Consumption Value Share by Type (2021-2026)

Figure 50. Global Tumor Biomarker Testing Market Share Forecast by Type (2027-2032)

Figure 51. Global Tumor Biomarker Testing Consumption Value Share by Application

(2021-2026)

Figure 52. Global Tumor Biomarker Testing Market Share Forecast by Application (2027-2032)

Figure 53. North America Tumor Biomarker Testing Consumption Value Market Share by Type (2021-2032)

Figure 54. North America Tumor Biomarker Testing Consumption Value Market Share by Application (2021-2032)

Figure 55. North America Tumor Biomarker Testing Consumption Value Market Share by Country (2021-2032)

Figure 56. United States Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 57. Canada Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 58. Mexico Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 59. Europe Tumor Biomarker Testing Consumption Value Market Share by Type (2021-2032)

Figure 60. Europe Tumor Biomarker Testing Consumption Value Market Share by Application (2021-2032)

Figure 61. Europe Tumor Biomarker Testing Consumption Value Market Share by Country (2021-2032)

Figure 62. Germany Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 63. France Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 64. United Kingdom Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 65. Russia Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 66. Italy Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 67. Asia-Pacific Tumor Biomarker Testing Consumption Value Market Share by Type (2021-2032)

Figure 68. Asia-Pacific Tumor Biomarker Testing Consumption Value Market Share by Application (2021-2032)

Figure 69. Asia-Pacific Tumor Biomarker Testing Consumption Value Market Share by Region (2021-2032)

Figure 70. China Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 71. Japan Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 72. South Korea Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 73. India Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 74. Southeast Asia Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 75. Australia Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 76. South America Tumor Biomarker Testing Consumption Value Market Share by Type (2021-2032)

Figure 77. South America Tumor Biomarker Testing Consumption Value Market Share by Application (2021-2032)

Figure 78. South America Tumor Biomarker Testing Consumption Value Market Share by Country (2021-2032)

Figure 79. Brazil Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 80. Argentina Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 81. Middle East & Africa Tumor Biomarker Testing Consumption Value Market Share by Type (2021-2032)

Figure 82. Middle East & Africa Tumor Biomarker Testing Consumption Value Market Share by Application (2021-2032)

Figure 83. Middle East & Africa Tumor Biomarker Testing Consumption Value Market Share by Country (2021-2032)

Figure 84. Turkey Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 85. Saudi Arabia Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 86. UAE Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)

Figure 87. Tumor Biomarker Testing Market Drivers

Figure 88. Tumor Biomarker Testing Market Restraints

Figure 89. Tumor Biomarker Testing Market Trends

Figure 90. Porters Five Forces Analysis

Figure 91. Tumor Biomarker Testing Industrial Chain

Figure 92. Methodology

Figure 93. Research Process and Data Source

## I would like to order

Product name: Global Tumor Biomarker Testing Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Product link: <https://marketpublishers.com/r/GE33691D6007EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE33691D6007EN.html>